🔊CEOInterviews

Leonard Marks on prostate cancer

From 22-11. Prof. Leonard Marks MD. "Contemporary Management of Prostate Cancer" · · ProstateForumofOrangeCounty

“It's not your father's prostate cancer — the paradigm has changed; MRI-guided biopsy has changed everything for prostate cancer management.”

Leonard Marks
Cofounder, Avenda Health
prostate cancerparadigm shiftMRI

On , Leonard Marks, Cofounder at Avenda Health, spoke about prostate cancer during 22-11. Prof. Leonard Marks MD. "Contemporary Management of Prostate Cancer" on ProstateForumofOrangeCounty.

22-11. Prof. Leonard Marks MD. "Contemporary Management of Prostate Cancer"
Watch on YouTube at 2:15
22-11. Prof. Leonard Marks MD. "Contemporary Management of Prostate Cancer"
ProstateForumofOrangeCounty
Watch on YouTube at 2:15
"This is not Your Father's Prostate Cancer." Dr. Marks talks about the revolutionary advances in detection of prostate cancer, and the target biopsy program at UCLA and elsewhere. Prostate Forum of Orange County is a Southern California Prostate Cancer Support Group, with online (Zoom) meetings on the second and fourth Tuesday of most months, beginning at 5:00 p. Pacific Time. Our website address is: www.prostateforum.org
Leonard Marks

About Leonard Marks

Cofounder · Avenda Health

In a November 2022 presentation to the Prostate Forum of Orange County, Leonard Marks, a UCLA urology professor and cofounder of Avenda Health, discussed what he described as a dramatic transformation in prostate cancer management. Marks stated that MRI-guided biopsy has "changed everything" and argued that biopsies for suspected prostate cancer should be preceded by an MRI, saying, "if you get the biopsy wrong the whole journey will be badly affected." He noted that his team was among the first in the United States to use the FDA-approved Artemis image-fusion device for targeted biopsies. Marks also discussed focal therapy options for localized prostate cancer, including cryotherapy, high-intensity focused ultrasound (HIFU), and focal laser ablation, which he said his startup is working to commercialize for use in a clinic rather than an operating room. He estimated that up to 40 percent of newly diagnosed prostate cancer cases may be candidates for focal therapy. Marks additionally highlighted the PSMA scan (Pylarify) as the most sensitive method for detecting metastases and noted that the PIRADS scoring system is used internationally, with PIRADS five lesions harboring clinically significant cancer about 80 percent of the time.

Profile compiled from Leonard Marks's verified public interviews and appearances. See all quotes & transcripts →

More from Leonard Marks Full Transcript Explore All Executives